TrexBio, a South San Francisco, CA-based discovery stage biotech company, raised $26M in Series A extension funding.
The round, which brings the total Series A funding raised to $85m, was led by Polaris Partners and Laurion Capital, with participation from SV Health Investors, Eli Lilly Company, Johnson & Johnson Innovation, Pfizer Ventures, and Alexandria Venture Investments. In conjunction with the financing, Alexandra Cantley, Ph.D., Partner at Polaris Partners will join the company’s Board of Directors. Alexander Duncan, Ph.D., Biotech Associate at Laurion Capital Management also joins as a Board Observer.
The company intends to use the funds for the continued expansion of its platform and the advancement of multiple programs through pre-IND activities.
Led by CEO Johnston Erwin, TRexBio is leveraging its proprietary Deep Biology platform to identify novel targets for therapeutics with a focus on modulating regulatory T cell (Treg) response in human tissue. The company is advancing multiple preclinical programs. The company leverages computational biology tools, focus on human tissue, and expertise in immunobiology to develop therapeutics for immune-mediated diseases. Its Deep Biology discovery engine maps human tissue Treg behavior to disease processes, allowing the company to identify and characterize novel targets for therapeutic intervention. Leveraging this platform, TrexBio is building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
The capital raise follows TRexBio’s recent announcement that it has entered into a multi-year research collaboration and licensing agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
FinSMEs
08/03/2022